Mechanical ventilation (MV) and extracorporeal membrane oxygenation (ECMO) are increasingly used to bridge patients to lung transplantation. We investigated the impact of using MV, with or without ECMO, before lung transplantation on survival after transplantation by performing a retrospective analysis of 826 patients who underwent transplantation at our high-volume center. Recipient characteristics and posttransplant outcomes were analyzed. Most lung transplant recipients (729 patients) did not require bridging; 194 of these patients were propensity matched with patients who were bridged using MV alone (48 patients) or MV and ECMO (49 patients). There was no difference in overall survival between the MV and MV+ECMO groups (p = 0.07). The MV+ECMO group had significantly higher survival conditioned on surviving to 1 year (median 1,811 days ([MV] vs. not reached ([MV+ECMO], p = 0.01). Recipients in the MV+ECMO group, however, were more likely to require ECMO after lung transplantation (16.7% MV vs. 57.1% MV+ECMO, p < 0.001). There were no differences in duration of postoperative MV, hospital stay, graft survival, or the incidence of acute rejection, renal failure, bleeding requiring reoperation, or airway complications. In this contemporary series, the combination of MV and ECMO was a viable bridging strategy to lung transplantation that led to acceptable patient outcomes.
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Introduction
Lung transplantation is the most effective therapy for end-stage lung disease, but the scope of its application is limited by the paucity of suitable donors (1) . The lung allocation score (LAS) was adopted in May 2005 to prioritize transplant recipients based on medical urgency rather the than length of time spent on the wait-list (2) . This was a deliberate bid to decrease wait-list mortality, but it has also led to an increase in the clinical acuity among lung transplant recipients because those with higher LAS preferentially draw organ offers. Thus, there has been a corresponding increase in demand for ventilator and mechanical support to bridge these critically ill patients to transplantation.
As recently as 2010, mechanical ventilation (MV) was considered a relative contraindication for lung transplantation, and so the emphasis the LAS placed on transplanting the sickest patients created somewhat of a controversy. The morbidity, mortality, and increased incidence of nosocomial respiratory infection associated with MV were considered factors leading to long-term immobility and consequent respiratory and physical deconditioning among ventilated recipients (3) . Indeed, many centers still cautiously approach MV as a bridge to lung transplantation and decline to list candidates (or delist candidates) once the recipient requires prolonged ventilator support. In high-volume centers, however, there has been a paradigm shift toward performing lung transplantation in patients with LASs in the highest tertile and a softening of attitudes toward the use of support before lung transplantation (4, 5) . This is, in part, because organs from available donors are preferentially directed toward the sickest patients and the centers caring for them.
There is, growing evidence, however, to justify the safety and utility of bridging strategies in lung transplantation (5) (6) (7) (8) . The combination of improved technology and clinical expertise, coupled with thoughtful, deliberate patient selection has yielded compelling evidence in support of bridging (10, 11) . As such, the use of bridging strategies has proliferated over the past decade (8) . Nevertheless, the decision to bridge patients to lung transplantation using MV, extracorporeal membrane oxygenation (ECMO), or both, remains contentious, and no matched comparison of bridging strategies has yet been reported. The purpose of this study was to evaluate pretransplantation MV, with and without ECMO support, as a bridge to lung transplantation. We also sought to identify risk factors for mortality among patients who survived to transplantation.
Methods

Patients
We performed a retrospective cohort study evaluating all patients (826 successive recipients) who underwent primary lung transplantation at our institution between January 2008 and December 2015. The entire cohort was divided into three groups: the control group (n = 729) comprised recipients who did not require MV before lung transplantation, the MVonly group (n = 48) comprised recipients who were bridged to lung transplantation on MV, and the MV+ECMO group (n = 49) comprised recipients who were bridged to lung transplantation with both MV and ECMO. We excluded recipients who had undergone combined heart-lung or combined lung/other organ transplantation. Our institutional recipient selection and standardized transplantation and ECMO protocols have been described in previous publications (6, 9) . Our institutional review board (IRB) approved this study.
Data abstraction
Recipient characteristics, donor characteristics, surgical characteristics, and postoperative variables were abstracted from our institutional database and electronic medical record. Recipient characteristics included demographics, body mass index (BMI), height, indication for lung transplantation, smoking history, oxygen requirement at rest, pulmonary function tests (PFTs), nutritional status, renal function, cardiac function, markers of infection, comorbidities, LAS, duration on wait-list, duration of MV, ECMO utilization, type of ECMO, tracheostomy requirement, and indication for MV. The indication for lung transplantation was classified by diagnostic category as defined in United Network for Organ Sharing (UNOS) policy 10.1.F.i (1). Diagnostic group A includes primarily obstructive lung diseases including bronchiectasis, chronic obstructive pulmonary disease, emphysema, lymphangioleiomyomatosis, and sarcoidosis without pulmonary arterial hypertension (PAH); group B includes primarily vascular diseases including Eisenmenger's syndrome, primary PAH, and pulmonary vascular disease; group C includes cystic fibrosis and immune deficiency; and group D includes bronchoalveolar carcinoma, eosinophilic granuloma, hemosiderosis, idiopathic pulmonary fibrosis, restrictive lung disease, sarcoidosis with PAH, and scleroderma/CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia).
The indication for MV was defined as "hypoxia" if the recipient had a pO 2 <60 mmHg on the day MV was initiated, and as "hypercarbia" if the recipient had a pCO 2 >60 mmHg on the day MV was initiated. Donor characteristics included demographics and cytomegalovirus (CMV) status. Surgical characteristics included type of lung transplantation (single or bilateral), ischemic time, use of cardiopulmonary bypass (CPB), and duration of CPB or intraoperative ECMO. Postoperative variables included duration of postoperative MV, ECMO utilization, length of hospital stay, complications, graft survival, time to re-transplantation, and overall survival. Complications included acute rejection, dialysis-dependent renal insufficiency, bleeding requiring reoperation, and airway complications (dehiscence, tracheobronchomalacia, strictures, obstruction, and fistulas). These characteristics were compared between each of the three groups.
Statistical analysis
The primary end-point was overall survival, with secondary end-points of length of postoperative MV, length of hospital stay, and incidence of complications. Multiple imputations were performed for variables with 5% to 20% missing data. Chi-square tests, Fisher exact tests, and logistic regression were used to compare categorical variables. Student's ttests, rank-sum tests, and linear regression were used to compare continuous variables. The following comparisons were performed: MV-only versus control, MV+ECMO versus control, and MV-only versus MV+ECMO.
A multivariable model to assess survival times by cohort adjusted for potential confounders was created using Cox regression. Patient, donor, and operative characteristics were individually paired with cohort membership in a two-variable regression model. Characteristics with p-value < 0.2 as determined by a Wald test were candidates for inclusion into the full multivariable model. Forward selection was then used to create the final multivariable Cox regression model. Variance inflation factors were calculated and showed no evidence of multicollinearity.
Propensity matching and analysis of the matched cohorts
A propensity score was derived for each patient based on transplant indication and age. A 2:1 nearest-neighbor match on propensity score was performed between the ventilated groups (MV only and MV+ECMO) and the control group. The propensity matching pertained to the nonbridged cohort and the bridged cohort as a collective group. Outcomes were compared between each of the groups using Chi-square and Fisher exact tests for categorical outcomes and Student's t-test and rank-sum test for continuous outcomes. Risk factors for mortality were found using logistic regression and backward elimination. Factors that were not statistically significant were progressively eliminated, beginning with the least significant predictors until only those factors that were statistically significant predictors remained in the model. A two-tailed p < 0.05 was considered statistically significant, and all analyses were performed using Stata 12.0 (StataCorp, College Station, TX).
Results
Of the 826 patients who underwent lung transplantation during the study period, 97 (11.7%) required MV prior to transplantation. Among the ventilated patients, 48 (49.5%) received MV only and 49 (50.5%) received both MV and ECMO. There were no statistically significant differences in sex, ethnicity, oxygen requirements, renal function, or cardiac function between the three groups ( Table 1) . As compared with patients who did not require MV prior to transplantation, recipients who required respiratory support (either MV only or MV+ECMO) were younger, less likely to be in diagnostic group A, more likely to be in diagnostic group C, and less likely to have been a former smoker (Table 1) . Patients who underwent MV without ECMO had lower BMI as compared with patients who did not require MV and had worse pulmonary function, as measured by percent of predicted forced expiratory volume in 1 s (FEV1) ( Table 1) . Patients who were bridged with both MV and ECMO were more likely to have pulmonary hypertension as compared with patients who received MV only and patients who did not receive respiratory support ( Table 1 ).
The indications for MV were similar in all patients who received MV. The average duration of MV prior to lung transplantation was 14 days for both groups of ventilated patients. These recipients who required bridging (MV only and MV+ECMO) were more likely to require tracheostomy as compared with recipients who did not, but the duration of tracheostomy was not significantly different between the three groups. (Table 1 ) Patients requiring MV and ECMO as a bridge had significantly higher LAS at the time of transplantation (median 90.39) and shorter time on the wait-list (median 13 days) than patients with no MV (median LAS 40.45, median wait 49 days) or patients with MV without ECMO (median LAS 85.07, median wait 33 days). Patients who required MV only had significantly higher LAS as compared with patients who did not require MV, but the length of time spent on the wait-list was not significantly different between the MV-only and no-MV groups.
Donor age, donor gender, and CMV mismatch rates were similar between the three groups ( Table 2) . Operative characteristics of the study population are displayed in Table 3 . MV-only and MV+ECMO patients were more likely to undergo bilateral lung transplantation as compared with patients who did not require MV. Although the proportion of patients who required intraoperative CPB was similar among the three groups, MV-only and MV+ECMO patients had a significantly longer duration of CPB during surgery than the patients who did not require MV prior to transplantation (Table 3) . MV-only and MV+ECMO patients were also more likely to require intraoperative ECMO (13.31% no MV vs. 31.25% MV only vs. 65.31%MV + ECMO) and a significantly longer duration of ECMO support (mean 249.91 vs. 309.00 vs. 405.78 min) as compared with patients who did not require MV prior to transplantation. MV+ECMO patients were more likely to require intraoperative ECMO than MV-only patients, but had similar ECMO times overall.
To analyze outcomes, patients were propensity matched by age and diagnostic category (Table 4) . Acceptable posttransplantation outcomes were observed for all three groups (Table 5 ). Patients requiring MV and ECMO as a bridge or MV without ECMO had significantly higher LAS at the time of transplantation than patients with no MV, even after propensity matching. This difference appears to be due to MV, since both MV groups have LAS elevated above the no MV group, and the MV+ECMO patients did not have LAS much higher than the MV-only patients. MV-only and MV+ECMO patients had significantly longer hospital stays after transplantation than patients who did not require MV prior to transplantation, but MV-only and MV+ECMO patients had hospital stays of similar duration (Table 5) . MV+ECMO patients were more likely to require postoperative ECMO as compared with both the no-MV and MV-only groups (9.79% no-MV vs. 16.67% MV-only vs. 57.14% MV+ECMO). MV+ECMO and MV-only patients were more likely to undergo reoperation for bleeding after lung transplantation (8.25% vs. 18.75% vs. 20.41%). Other complications, such as dialysis-dependent renal insufficiency, airway complications, and acute rejection, were not significantly different between the three groups. The need for retransplantation also did not differ significantly between the three groups.
The use of MV, with or without ECMO, prior to transplantation did not significantly affect overall survival (Figure 1) . Although survival for MV and MV+ECMO patients appears to decrease in the first few months posttransplantation, this difference is not statistically significant. On the other hand, the use of MV and ECMO as a bridge before transplantation compared with MV only showed significantly greater survival conditioned on survival to 1 year (Figure 2) .
A multivariable Cox proportional hazard model was created to compare risk of death between the control, MV-only, and MV+ECMO groups while controlling for potential confounders. Postestimation based on the final model (Table 6) indicates that the MV+ECMO group had a lower risk of death than both the control group (hazard ratio [HR] 0.38, p = 0.048) and the MV-only group (HR 0.33, p = 0.030) ( Table 6 ).
Risk factors for mortality were found using logistic regression and eliminating factors from the model that were not significant. This process was applied to the control group, the MV-only group, and the MV+ECMO group. Potential risk factors that were considered in the model included all patient characteristics, comorbidities, donor characteristics, and operative characteristics (as listed in Tables 1-4 
Discussion
Using the LAS to prioritize lung transplant recipients has increased demand for bridging strategies, such as ECMO and MV. This has also increased the need to better understand the impact of bridging on postoperative recovery and survival. This study demonstrated that MV plus ECMO survival is different from MV-only survival, and it is more similar to (if not better than) the standard or control arm at 3 years. Hence this combination of MV and ECMO is a viable bridging strategy that leads to acceptable patient outcomes. The use of MV or MV and ECMO before transplantation is often associated with more complicated operative procedures, as evidenced by a longer duration of CPB during the transplant surgery and a higher likelihood of requiring intraoperative ECMO, and has been associated with longer hospital stays and a higher likelihood for reoperation. It is important to note, however, that MV or MV with ECMO as a bridge to lung transplantation did not lead to statistically significant differences in most postoperative complications or in overall survival. In fact, the use of MV with ECMO as a bridge to transplantation significantly increased survival as compared with MV alone.
Over the past decade, significant advances in technology and clinical expertise have led to a vast improvement in outcomes using ECMO to bridge to lung transplantation and have resulted in a near equivalency in 1-year survival as compared with patients transplanted without any form of bridging and a near doubling in 5-year survival from 25% to the current 50% (7). As a direct consequence, a paradigm shift has occurred with a departure from previously held assumptions that a patient requiring support was "too sick" to undergo transplantation (3,4).
Our results confirm that the heightened clinical acuity and sense of urgency associated with the initiation of mechanical support prompts an increase in LAS that may afford the patient the benefit of a shorter time on the wait-list and higher likelihood of double-lung transplantation, which is associated with improved long-term survival in some patient groups, although this remains contested (10, 11) . This is also likely to be at least partially responsible for the dramatic improvement in outcomes over the past 5 years (7). These improvements have, in turn, fueled impetus to rely on the use of bridging strategies to manage the sickest recipients and support them until transplantation.
It may be argued that the incentivization of high-risk transplantation is precisely what the LAS system was designed to achieve (12) . An unintended consequence of this trend, however, has been preferentially redirecting donated organs to centers that cater to patients of high acuity, and consequently decreasing the availability of donated organs at centers that are more risk averse, poorly resourced, or without the infrastructure for ECMO or multidisciplinary rehabilitation. This may inadvertently create a determining criterion as to whether transplant centers will be able to achieve and maintain high-volume status.
Although mechanical support has been somewhat the domain of high-volume centers, the preferential allocation of organs to high-acuity candidates may soon coerce low-volume centers to accept the challenge of catering to sicker patients. This may dictate an expansion of their intensive care capabilities and a deliberate development of extracorporeal support infrastructure (13, 14) . The demand for quality-driven performance measures will likely follow and push for the establishment of centers of excellence. This may influence decision-making algorithms to promote earlier institution of ECMO to avoid the collateral damage caused by multisystem organ failure. All centers need not be expected to diversify to independently provide all service, but low-volume centers will not attract the optimal number of donated organs to 27 (21) 39 (23) 36 ( sustain or increase their volumes if the majority of donated organs continue to be directed to centers more willing and able to care for the sickest patients. This raises the argument for regionalization of care or the reorganization of organ procurement organization zones.
Our results challenge some existing decision-making algorithms that may not feature bridging options, because our findings endorse the use of MV and ECMO as viable bridging strategies. Like other reports that have evaluated the contemporary use of mechanical support, we confirmed that ventilated patients have equivalent longterm survival and allograft function as compared with nonventilated patients (15) (16) (17) (18) . Some previous studies have been limited by small sample sizes, narrow cohort characteristics, and an overall heterogeneity. Furthermore, much of the reported data predates the current LAS system. Our results refute reports using data from the Scientific Registry of Transplant Recipients (SRTR) United Network for Organ Sharing (UNOS) database that indicated that ventilated patients have poorer short-term posttransplantation survival than nonventilated patients (3). Those conclusions were based on national aggregates without the granular detail needed to capture all potentially relevant risk factors that contribute to patient outcomes, such as the duration of MV, indication for ventilation, markers of infection, nutritional status, and the incidence and impact of complications.
The survival findings of our study were surprising. After the first year posttransplantation, recipients bridged to lung transplantation on MV with ECMO had better survival than those bridged using MV alone. In addition, and far more surprisingly, MV+ECMO patients had better survival than patients who did not receive either MV or ECMO before lung transplantation. As mentioned previously, this may be a reflection of the increased use of double lung transplantation in MV+ECMO patients. It may also reflect the technology-driven advances that have made ECMO a safe alternative as a bridge to transplantation. The higher overall LAS in patients requiring MV and ECMO may signify that a higher prioritization for donor lungs and shorter time spent on the waiting list also each play a role.
In our study, we observed a deleterious effect of CMV mismatch on survival. This will likely require further analysis to better inform the dosing and duration of anti-viral prophylaxis regimens so as to best prevent CMV reactivation or viremia and its subsequent effect on survival (18- Number at risk by time 20). We also observed an increased risk of reoperation in patients who required MV and ECMO for bridging, but this seems to be adequately mitigated and limited in its impact on survival. This may also be a reflection of the aggregate of advanced intensive care, overall transplant volume, and cumulative clinical experience garnered over the years to allow effective management of complex cases (22) . It may also reflect a robust ability to expeditiously rescue patients when it is necessary. By understanding and anticipating the mortality after transplantation associated with advanced age, renal failure, long ischemic times, and CMV mismatch, centers may better select patients for bridging, further mitigate the mortality burden, and enhance the selection process as to who should be bridged and how (MV vs ECMO (21-24) ). There is likely to remain a growing interest in the use of ambulatory ECMO, without the use of MV, to avoid sedation and immobilization and prevent collateral morbidity from multisystem organ failure that has plagued traditional ECMO in the past (25, 26) .
Based on the findings of this study and for the first time in the literature, we offer the theory that once medical therapy has failed, surgical input should be more aggressively pursued to add to the treatment algorithm an early option for rapid escalation to veno-venous or veno-arterial ECMO support, that may afford the survival advantage that we observed. This raises the assertion that surgical teams should likely be more involved in the management of terminal end-stage lung disease so as to more quickly offer those components of the contemporary surgical armamentarium and evolving technological advances that might be of assistance in the event of failure of medical therapy.
The study has limitations. First, it is a retrospective study based on a single institutional experience. As such, our results may not necessarily be generalizable to other institutions. Consequently the results may be subject to inherent bias including selection bias and undetectable bias despite the propensity matching. Second, the study does not adjust for the effect of contemporary improvements in anesthesia, diagnostics, pharmaceutical and transfusion protocols, or intensive care delivery, each of which undoubtedly influences outcomes and survival. Third, the study does not adjust for a possible era effect or for other generational confounders inherent in the context of a continually evolving medical landscape. In addition, we acknowledge that our analysis pertains only to those recipients who survived to lung transplantation and this may introduce a selection bias. Further analyses focusing on these nonsurvivors are currently being conducted. Our preliminary results, however, have shown that approximately 25-30% of prospective recipients died while being bridged to transplantation, with the greater proportion being those on mechanical ventilation. Patients with pulmonary hypertension were at greatest risk for early mortality. The reasons for this are speculative at this stage but will likely be better elucidated as we complete the analysis. The study's strength, however, is the provision of rich, granular detail pertaining to lung transplantation recipients, which provides a depth of perspective that is often lacking in current published analyses that are based solely on aggregate data from administrative datasets. The study also has the benefit of homogeneity of a single institution with standardized protocols, surgical techniques, and management algorithms as well as the largest series of transplantations in North America. To the best of our knowledge, this is the first report of a study of this magnitude to discuss outcomes directly comparing bridging strategies. Lung transplant centers, such as ours, will need to increasingly rely on bridging strategies to support candidates until a suitable donor is secured, particularly in view of the current shortage of acceptable donors. Our results, although compelling, warrant further exploration in the form of a randomized study. We anticipate that further validation will come from other high-volume centers that will further ensure the transplant community that our results are not just a single-institution phenomenon and that that our results are not just a single-institution phenomenon and that broader investigation may be warranted.
In conclusion, the use of bridging strategies in lung transplantation has improved sufficiently over the past decade to produce an acceptable risk and morbidity profile. There is growing proof to justify the candidacy of patients with high clinical acuity who require either MV or ECMO to bridge them to transplantation. The exacerbation of underlying pulmonary disease should no longer be grounds for automatic disqualification from consideration for transplantation. Indeed, swift recognition of the need for and initiation of appropriate bridging support may yield equal and possibly even better results than are seen in patients who do not receive bridging support. Our findings challenge the notion that ventilatory or extracorporeal circulatory support is a contraindication for lung transplantation and highlight the need for large, detailed analyses of risk factors and outcomes in lung transplantation candidates with high clinical acuity.
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